Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib + Paclitaxel in HER2-Negative/Unknown Metastatic Breast Cancer
NCT00075270Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2004
- Primary completion
- Oct 2006
- Modality
- Small Molecules
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Lapatinib + Paclitaxel with Placebo + Paclitaxel (2 arms). Primary endpoint: Time to Progression at 26 weeks. Started Jan 2004; status: completed.
02
Drugs
lapatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00075270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00075270.